Healthcare
OrbiMed raises $800m for Asia life sciences fund
OrbiMed has closed its latest Asia life sciences fund, which primarily invests in China and India, with $800 million in commitments.
Lunar buys majority stake in Hong Kong IVF business
Chinese middle-market buyout firm Lunar has agreed to acquire a women’s health and IVF business from Mason Group, a Hong Kong conglomerate with interests in financial services and healthcare, for HK$268 million ($34.5 million).
China's WuXi Diagnostics raises $150m
WuXi Diagnostics, a joint venture China diagnostics business set up by Hong Kong-listed pharmaceutical outsourcing giant WuXi AppTec and US-based Mayo Clinic has completed a $150 million Series B funding round.
LeapFrog names co-head of healthcare
Asia and Africa-focused impact investor LeapFrog Investments has recruited Biju Mohandas as a partner and global co-lead for healthcare.
China’s Clover Biopharmaceuticals gets $230m Series C
Chengdu-based Clover Biopharmaceuticals has raised $230 million in Series C funding led by GL Ventures and Temasek Holdings. Oceanpine Capital, OrbiMed, and Delos Capital all re-upped.
China's AnchorDx completes $40m Series C
AnchorDx, a China-based medical technology developer focused on DNA sequencing and diagnostics, has raised a $40 million Series C round led by OrbiMed and WuXi Huiying Investment.
China’s Regor Therapeutics raises $90m Series B
Lilly Asia Ventures (LAV) has led a $90 million Series B round for Regor Therapeutics, a Chinese drug developer specializing in bioinformatics.
China cancer screening business gains on Hong Kong debut
New Horizon Health, a China-based and venture capital-backed cancer early screening company, rose 215% on its trading debut following a HK$2 billion ($258 million) Hong Kong IPO.
China's CITIC sells US dental business
CITIC Capital Partners has exited US-based dental business DDS Lab – the private equity firm’s first acquisition in the US as a lead investor – to RoundTable Healthcare Partners for an undisclosed sum.
Chinese virotherapy specialist Binhui Biotech raises $93m
Wuhan-based Binhui Biotech has raised RMB600 million ($93 million) in Series C funding led by Shenzhen-based Share Capital. Other investors include CICC Capital, Vertex Ventures China and Qianhai FOF under Shenzhen Capital Group.
Deal focus: CPE backs MicroPort's medical devices agenda
CPE has backed a string of spinouts from Chinese medical device manufacturer MicroPort Medical. MicroPort CardioFlow Medtech’s Hong Kong IPO represents its first liquidity event
China's Cloopen, Adagene complete strong US IPOs
Cloud services provider Cloopen and biotech developer Adagene, both backed by Sequoia Capital China, have raised a combined $460 million in their US IPOs.
New Frontier to privatize US-listed China hospital business
The New Frontier Group-led consortium that acquired Chinese hospital operator United Family Healthcare (UFH) through a special purpose acquisition company (SPAC) in 2019 is now looking to take the US-listed business private at a valuation of around $1.6...
Sequoia, Tencent lead Series E for China’s Miaoshou Doctor
Beijing Yuanxin Technology, operator of China-based online healthcare services platform Miaoshou Doctor, has raised RMB3 billion ($466 million) in Series E funding led by Sequoia Capital China and Tencent Holdings.
MBK targets $639m acquisition of Japan aged care business
MBK Partners has joined the list of private equity firms pursuing deals in Japan’s aged care and healthcare space, having launched a tender offer for Tsukui Holdings Corporation at a valuation of JPY66.9 billion ($639 million).
Advent buys majority stake in India's ZCL, MSPEA exits
Advent International has agreed to acquire Indian pharmaceuticals supplier ZCL Chemicals, setting up a minority exit for Morgan Stanley Private Equity Asia (MSPEA).
Indigenous New Zealand LP backs pathology business
Te Puia Tapapa (TPT), a PE investor serving New Zealand indigenous groups, has backed a pathology business owned by New Zealand Superannuation Fund (NZ Super) and Ontario Teachers’ Pension Plan (OTPP).
Carlyle, Brighton Park invest $200m in India's Indegene
The Carlyle Group and US GP Brighton Park Capital have committed a combined $200 million to Indegene, an Indian technology provider for the healthcare and life sciences industries.
Tencent leads Series C for China gene sequencing player
Guangzhou-based precision diagnosis and gene sequencing company Vision Medicals has raised RMB200 million ($31 million) in Series C funding led by Tencent Holdings.
Temasek impact arm leads Series B for Vietnam dental player
ABC World Asia, the impact investment arm of Temasek Holdings, has led a $24 million Series B found for Kim Dental, a Vietnam-based dental clinic operator. Existing backer Aura Private Equity also participated.
Lilly Asia Ventures raises $1.35b for healthcare funds
Lilly Asia Ventures (LAV) has raised $1.35 billion for its latest healthcare fund, having introduced a $450 million opportunity vehicle that sits alongside a core pool of $900 million.
CLSA partially exits Japan medical IT provider
CLSA Capital Partners (CLSA CP) has partially exited its position in NHOSA Corporation, a Japanese IT provider for dental clinics and medical institutions.
General Atlantic backs Indonesia biotech developer
General Atlantic has invested $55 million in Kalbe Genexine Biologics, an Indonesia-based drug developer focusing on Southeast Asia.
Fund focus: LPs flock to Lake Bleu’s late show
Lake Bleu Capital leveraged a lift in Chinese healthcare sentiment to raise $560 million for a fund that will target late-stage healthcare investments